← Back to Search

Monoclonal Antibodies

REGN5715 for Allergy or Hay Fever

Phase 2
Waitlist Available
Research Sponsored by Regeneron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented or participant-reported history of birch tree pollen-triggered allergic-rhinitis (AR) symptoms with or without conjunctivitis (for at least 2 seasons)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 29, 57, 85 and 127
Awards & highlights

Study Summary

This trialtests if anti-birch allergy antibodies reduce symptoms of allergic reaction to birch pollen.

Eligible Conditions
  • Allergy (or Hay Fever)
  • Pink Eye

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have experienced allergic reactions to birch tree pollen that caused symptoms like runny nose and itchy eyes for at least two seasons.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 29, 57, 85 and 127
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 29, 57, 85 and 127 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean of Total Nasal Symptom Score [TNSS (2 to 6 hours)] during a birch allergen environmental exposure unit (EEU) challenge
Secondary outcome measures
Change from baseline in CSMS averaged during the BPS
Change from baseline in CSMS averaged during the peak BPS
Change from baseline in DMS averaged during the BPS
+78 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: REGN5715Experimental Treatment2 Interventions
1-mAb
Group II: REGN5713-5715Experimental Treatment3 Interventions
2-mAb
Group III: REGN5713-5714-5715Experimental Treatment3 Interventions
3-mAb
Group IV: Matching PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
REGN5713
2022
Completed Phase 3
~570
REGN5714
2022
Completed Phase 3
~570
REGN5715
2022
Completed Phase 3
~570

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
613 Previous Clinical Trials
379,242 Total Patients Enrolled
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
258 Previous Clinical Trials
250,482 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there long-term repercussions to using REGN5713-5714-5715?

"REGN5713-5714-5715 has yet to be proven effective in clinical trials, however, there is some safety data supporting its use. Consequently, our team scored it a 2."

Answered by AI

Are people with the required qualifications able to sign up for this experiment currently?

"The study, which was published on clinicaltrials.gov on 8/15/2022 is still recruiting participants. The last edit to the posting was made on 10/13/2022."

Answered by AI

How many individuals are being added to this clinical trial?

"The data available on clinicaltrials.gov supports that this study is open for recruitment and actively looking for participants. This trial was first posted on August 15th, 2020 and was last edited on October 13th, 2020. The study needs to recruit 300 patients from 2 sites in order to continue."

Answered by AI
~84 spots leftby Mar 2025